"Loss of Heterozygosity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.
| Descriptor ID |
D019656
|
| MeSH Number(s) |
G05.365.590.029.530
|
| Concept/Terms |
Loss of Heterozygosity- Loss of Heterozygosity
- Heterozygosity Loss
- Allelic Loss
- Allelic Losses
- Heterozygosity, Loss of
|
Below are MeSH descriptors whose meaning is more general than "Loss of Heterozygosity".
Below are MeSH descriptors whose meaning is more specific than "Loss of Heterozygosity".
This graph shows the total number of publications written about "Loss of Heterozygosity" by people in this website by year, and whether "Loss of Heterozygosity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 6 | 6 |
| 2002 | 1 | 3 | 4 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 3 | 4 |
| 2009 | 1 | 1 | 2 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 0 | 3 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 3 | 3 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Loss of Heterozygosity" by people in Profiles.
-
Determinants of mosaic chromosomal alteration fitness. Nat Commun. 2024 May 07; 15(1):3800.
-
Recurrent Loss of Heterozygosity in Pancreatic Neuroendocrine Tumors. Am J Surg Pathol. 2022 06 01; 46(6):823-831.
-
Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study. Gynecol Oncol. 2022 02; 164(2):245-253.
-
A pan-cancer organoid platform for precision medicine. Cell Rep. 2021 07 27; 36(4):109429.
-
Germline BRCA-Associated Endometrial Carcinoma Is a Distinct Clinicopathologic Entity. Clin Cancer Res. 2019 12 15; 25(24):7517-7526.
-
Radiation-Induced DNA Damage Cooperates with Heterozygosity of TP53 and PTEN to Generate High-Grade Gliomas. Cancer Res. 2019 07 15; 79(14):3749-3761.
-
Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 01 10; 37(2):115-124.
-
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. Clin Breast Cancer. 2018 04; 18(2):184-188.
-
Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. Oncotarget. 2017 Mar 21; 8(12):18726-18734.
-
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. Breast Cancer Res. 2016 11 11; 18(1):112.